Interpace Diagnostics to Present at American Thyroid Association

Interpace Diagnostics Group (NASDAQ: IDXG) announced that it will have two poster presentations at the 86th Annual Meeting of the American Thyroid Association, which takes place on September 15, 2016. These studies will focus on product candidates ThyGenX and ThyraMir.
As quoted in the press release:

“The first of the two posters entitled “Molecular Analysis of Thyroid Malignancy Using Cytology Smears by Combined THYGENX™ and THYRAMIR™ testing: A Prospective Study” highlights the clinical performance of the combined ThyGenX + ThyraMIR tests when carried out on Fine Needle Aspirate (FNA) material smeared on cytology slides.
The second poster entitled “The Majority of Non-Diagnostic (Insufficient) Thyroid Nodule Cytology Samples Can Effectively Undergo Molecular (Combined Mutational and MicroRNA Classifier) Analysis Using a Needle Aspiration Approach” demonstrates that Interpace’s scientists were able to perform molecular analysis in cases where cytology results were insufficient.”

According to Jack Stover, Interpace’s CEO:

“Both of these posters being accepted by an organization as influential as the ATA indicates that the innovative work we do is critically important and ultimately affects both the cost and the quality of care provided to patients with suspected thyroid cancer.”

Read the full press release here.